{"id":9540,"date":"2022-07-29T12:26:52","date_gmt":"2022-07-29T10:26:52","guid":{"rendered":"https:\/\/www.clib-cluster.de\/ginkgo-to-acquire-zymergen\/"},"modified":"2022-07-29T12:28:25","modified_gmt":"2022-07-29T10:28:25","slug":"ginkgo-to-acquire-zymergen","status":"publish","type":"post","link":"https:\/\/www.clib-cluster.de\/en\/ginkgo-to-acquire-zymergen\/","title":{"rendered":"Ginkgo to Acquire Zymergen"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-9536 size-medium\" src=\"https:\/\/www.clib-cluster.de\/wp-content\/uploads\/\/Ginkgo-Logo-Lockup-1-Color-e1659090488874-300x97.png\" alt=\"\" width=\"300\" height=\"97\" srcset=\"https:\/\/www.clib-cluster.de\/wp-content\/uploads\/Ginkgo-Logo-Lockup-1-Color-e1659090488874-300x97.png 300w, https:\/\/www.clib-cluster.de\/wp-content\/uploads\/Ginkgo-Logo-Lockup-1-Color-e1659090488874-1030x332.png 1030w, https:\/\/www.clib-cluster.de\/wp-content\/uploads\/Ginkgo-Logo-Lockup-1-Color-e1659090488874-768x248.png 768w, https:\/\/www.clib-cluster.de\/wp-content\/uploads\/Ginkgo-Logo-Lockup-1-Color-e1659090488874-1536x495.png 1536w, https:\/\/www.clib-cluster.de\/wp-content\/uploads\/Ginkgo-Logo-Lockup-1-Color-e1659090488874-2048x660.png 2048w, https:\/\/www.clib-cluster.de\/wp-content\/uploads\/Ginkgo-Logo-Lockup-1-Color-e1659090488874-1500x483.png 1500w, https:\/\/www.clib-cluster.de\/wp-content\/uploads\/Ginkgo-Logo-Lockup-1-Color-e1659090488874-705x227.png 705w, https:\/\/www.clib-cluster.de\/wp-content\/uploads\/Ginkgo-Logo-Lockup-1-Color-e1659090488874-600x193.png 600w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<div class=\"module_body\">\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li><i>Acquisition is expected to accelerate the development of Ginkgo&#8217;s innovative horizontal synthetic biology platform<\/i><\/li>\n<li><i>Expect integration of Zymergen&#8217;s complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo&#8217;s platform for its diverse customer base and enable new growth opportunities across many end markets<\/i><\/li>\n<li><i>Zymergen&#8217;s core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the acquisition<\/i><\/li>\n<li><i>Ginkgo&#8217;s platform serves customers across industries as an enabling platform and Ginkgo will support Zymergen&#8217;s plans to evaluate strategic alternatives for their Advanced Materials and Drug Discovery businesses<\/i><\/li>\n<li><i>Zymergen stockholders will own 5.25% of the pro forma combined company following the transaction<\/i><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p><span class=\"legendSpanClass\">BOSTON and EMERYVILLE, Calif.<\/span>,\u00a0<span class=\"legendSpanClass\">July 25, 2022<\/span>\u00a0\/PRNewswire\/ &#8212;\u00a0Today, Ginkgo Bioworks (NYSE: DNA) \u2014 the leading horizontal platform for cell programming \u2014 and the biotechnology company Zymergen (Nasdaq: ZY) announced they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization. Under the terms of the agreement, which have been unanimously approved by the boards of directors of both companies, Zymergen stockholders will receive a fixed exchange ratio of 0.9179 Ginkgo shares for each Zymergen share, representing 5.25% pro forma ownership of Ginkgo following the transaction.<\/p>\n<p><a href=\"https:\/\/investors.ginkgobioworks.com\/news\/news-details\/2022\/Ginkgo-to-Acquire-Zymergen\/\" target=\"_blank\" rel=\"noopener\">Read more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acquisition is expected to accelerate the development of Ginkgo&#8217;s innovative horizontal synthetic biology platform Expect integration of Zymergen&#8217;s complementary automation, software, and data science tools as well as biological assets [&hellip;]<\/p>\n","protected":false},"author":21,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[145],"tags":[],"class_list":["post-9540","post","type-post","status-publish","format-standard","hentry","category-third-party-news"],"_links":{"self":[{"href":"https:\/\/www.clib-cluster.de\/en\/wp-json\/wp\/v2\/posts\/9540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.clib-cluster.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.clib-cluster.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.clib-cluster.de\/en\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/www.clib-cluster.de\/en\/wp-json\/wp\/v2\/comments?post=9540"}],"version-history":[{"count":0,"href":"https:\/\/www.clib-cluster.de\/en\/wp-json\/wp\/v2\/posts\/9540\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.clib-cluster.de\/en\/wp-json\/wp\/v2\/media?parent=9540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.clib-cluster.de\/en\/wp-json\/wp\/v2\/categories?post=9540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.clib-cluster.de\/en\/wp-json\/wp\/v2\/tags?post=9540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}